Vaccine answers lead to more questions

Coronavirus Daily
Bloomberg

Here's the latest news from the global pandemic.

Vaccine answers lead to more questions

When Pfizer and BioNTech released positive vaccine results Monday, the floodgates of optimism opened.

The companies' announcement of more than 90% effectiveness in a study of some 44,000 people suggested that a way out of the pandemic may be at hand. Airwaves were flooded with scientists and other observers explaining the findings, and equity indexes gained as long-battered travel and entertainment stocks soared.

Yet many questions about the vaccine—who it protects, for how long, and from what—still remain to be answered. The study was designed primarily to show that the shot wards off symptomatic cases of Covid-19, not infections. It still needs to show whether those who get the vaccine are less likely to suffer severe, potentially deadly forms of the disease.

Its performance in key groups such as the elderly and people with chronic health conditions like diabetes is to be determined. And the four-month-old study can't tell us how long protection lasts.

Photographer: NurPhoto/NurPhoto

Photographer: NurPhoto/NurPhoto

Even when all these boxes are ticked, the vaccine must be manufactured, distributed and administered. The companies expect to make some 50 million doses this year and about 1.3 billion in 2021. But divide those numbers in half, because each person needs two shots to be immunized.

Then there's the challenge of storing the vaccine at ultra-low temperatures, requiring equipment many communities lack, even in the U.S.

It's also important to continue watching those who received the vaccine for years. The messenger RNA technology used in the Pfizer/BioNTech vaccine has never been deployed in humans before.

That adds up to many more questions and a lot more work from governments, scientists and health workers.

"A positive signal would be exciting," said Richard Hatchett, chief executive officer of the Coalition for Epidemic Preparedness Innovations, "but it certainly wouldn't mean that the pandemic is about to be over."—John Lauerman

Podcast Special Edition 

The Next Year of the Virus

Eight months into the pandemic, the coronavirus is on a rampage around the world. In Europe, surging infections spur new lockdowns. The U.S. is entering its most dangerous period yet. With Michelle Fay Cortez and Robert Langreth, we look back at how we got here, and ahead to what's next for the outbreak. Get the episode here.

 

What you should read

2020 Holiday Entertaining Is Tricky. Here's Help
Holiday parties will be different, but that doesn't mean they won't happen.
How a Shot Could Actually Help the Virus Spread
Possibility of infecting others after a shot is a risk that's gotten little attention.
U.K. Mobilizes for Shot Redemption After Missteps
Its erratic crisis response fuels concern it may bungle vaccine distribution. 
Tokyo's Noodle Bars Shut Rather Than Up Prices
Covid upends businesses relying on cheap food and elbow-to-elbow dining.
Lost Opportunities for Asia's Lockdown Generation
Largest group of world's young adults may not do better than their parents.

Know someone else who would like this newsletter? Have them sign up here.

Have any questions, concerns, or news tips on Covid-19 news? Get in touch or help us cover the story.

Like this newsletter? Subscribe for unlimited access to trusted, data-based journalism in 120 countries around the world and gain expert analysis from exclusive daily newsletters, The Bloomberg Open and The Bloomberg Close.

Comments

Popular posts from this blog

अभिषेक बच्चन ने कहा- पापा ने मेरे लिए कभी कोई फिल्म नहीं बनाई, उन्होंने कभी मेरी मदद नहीं की

The speech that sunk the world's biggest IPO

James Gunn Confirms ‘The Suicide Squad’ Panel For CCXP Worlds